Pancreatic Adenocarcinoma Clinical Trials

126 recruitingLast updated: June 17, 2026

There are 126 actively recruiting pancreatic adenocarcinoma clinical trials across 23 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Pancreatic Adenocarcinoma Trials at a Glance

126 actively recruiting trials for pancreatic adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 58 trials, with the heaviest enrollment activity in Houston, New York, and San Antonio. Lead sponsors running pancreatic adenocarcinoma studies include Mayo Clinic, Revolution Medicines, Inc., and Ruijin Hospital.

Browse pancreatic adenocarcinoma trials by phase

Treatments under study

About Pancreatic Adenocarcinoma Clinical Trials

Looking for clinical trials for Pancreatic Adenocarcinoma? There are currently 63 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 126 trials

Recruiting
Not Applicable

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma+1 more
Alpha Tau Medical LTD.15 enrolled2 locationsNCT05657743
Recruiting
Not Applicable

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma
Alpha Tau Medical LTD.40 enrolled15 locationsNCT06698458
Recruiting
Not Applicable

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

Pancreatic CancerPancreatic AdenocarcinomaUnresectable Pancreatic Cancer
Alpha Tau Medical LTD.15 enrolled1 locationNCT06026943
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled454 locationsNCT04858334
Recruiting
Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.670 enrolled3 locationsNCT07621718
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled17 locationsNCT07562152
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Adenocarcinoma
National Cancer Institute (NCI)92 enrolled44 locationsNCT04172532
Recruiting
Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled46 locationsNCT05365581
Recruiting
Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast CancerOvarian CancerColorectal Carcinoma+4 more
AstraZeneca45 enrolled18 locationsNCT05877599
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Non-small Cell Lung Cancer (NSCLC)Ovarian CancerEndometrial Cancer+4 more
Shenzhen Ionova Life Sciences Co., Ltd.178 enrolled1 locationNCT07610798
Recruiting
Phase 2

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic Adenocarcinoma
Mayo Clinic43 enrolled3 locationsNCT07226856
Recruiting
Phase 1Phase 2

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Breast CancerOvarian CancerProstate Cancer+6 more
University of Florida29 enrolled1 locationNCT05000294
Recruiting
Phase 1Phase 2

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Pancreatic AdenocarcinomaGastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.150 enrolled9 locationsNCT07488676
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled5 locationsNCT07491445
Recruiting
Phase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.614 enrolled17 locationsNCT07409272
Recruiting
Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Not Applicable

MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer

Pancreatic Adenocarcinoma
Ohio State University Comprehensive Cancer Center30 enrolled1 locationNCT07619391